These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 1131393)
21. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Sladek NE; Doeden D; Powers JF; Krivit W Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951 [TBL] [Abstract][Full Text] [Related]
22. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)]. Voelcker G; Haeglsperger R Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370 [TBL] [Abstract][Full Text] [Related]
23. Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry. Baumann F; Lorenz C; Jaehde U; Preiss R J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):297-305. PubMed ID: 10410955 [TBL] [Abstract][Full Text] [Related]
24. Identification of new metabolites of phosphoramide and nor-nitrogen mustards and cyclophosphamide in rat urine using ion cluster techniques. Chan KK; Hong SC; Watson E; Deng SK Biomed Environ Mass Spectrom; 1986 Mar; 13(3):145-54. PubMed ID: 2938656 [TBL] [Abstract][Full Text] [Related]
25. Kinetics of hydrolysis in vitro of nornitrogen mustard, a metabolite of phosphoramide mustard and cyclophosphamide. Hemminki K; Alhonen A; Linkola E; Hesso A Arch Toxicol; 1987 Dec; 61(2):126-30. PubMed ID: 3439884 [TBL] [Abstract][Full Text] [Related]
26. Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry. Przybylski M; Ringsdorf H; Voelcker G; Draeger U; Peter G; Hohorst HJ Cancer Treat Rep; 1976 Apr; 60(4):509-16. PubMed ID: 1277228 [TBL] [Abstract][Full Text] [Related]
27. [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)]. Wagner T; Heydrich D; Voelcker G; Hohorst HJ J Cancer Res Clin Oncol; 1980 Jan; 96(1):79-92. PubMed ID: 7358774 [TBL] [Abstract][Full Text] [Related]
28. Review of the metabolism and mode of action of cyclophosphamide. Fenselau C J Assoc Off Anal Chem; 1976 Sep; 59(5):1028-36. PubMed ID: 965325 [TBL] [Abstract][Full Text] [Related]
29. Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood. Anderson LW; Ludeman SM; Colvin OM; Grochow LB; Strong JM J Chromatogr B Biomed Appl; 1995 May; 667(2):247-57. PubMed ID: 7663697 [TBL] [Abstract][Full Text] [Related]
30. Determination of cyclophosphamide metabolites by gas chromatography and thermionic specific detection. Interindividual differences in hepatic biotransformation of cyclophosphamide in man in vitro. Sessink PJ; Vaes WH; van den Broek PH; Noordhoek J; Bos RP J Chromatogr B Biomed Appl; 1995 Nov; 673(2):205-12. PubMed ID: 8611954 [TBL] [Abstract][Full Text] [Related]
31. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes. Cox PJ; Phillips BJ; Thomas P Cancer Treat Rep; 1976 Apr; 60(4):321-6. PubMed ID: 179712 [TBL] [Abstract][Full Text] [Related]
32. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites. Boyd VL; Robbins JD; Egan W; Ludeman SM J Med Chem; 1986 Jul; 29(7):1206-10. PubMed ID: 3543359 [TBL] [Abstract][Full Text] [Related]
33. Aldophosphamide: synthesis, characterization, and comparison with "Hohorst's aldophosphamide". Struck RF Cancer Treat Rep; 1976 Apr; 60(4):317-9. PubMed ID: 1277207 [TBL] [Abstract][Full Text] [Related]
34. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide. Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629 [TBL] [Abstract][Full Text] [Related]
35. Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry. Kalhorn TF; Howald WN; Cole S; Phillips B; Wang J; Slattery JT; McCune JS J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May; 835(1-2):105-13. PubMed ID: 16581318 [TBL] [Abstract][Full Text] [Related]
36. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Dirven HA; van Ommen B; van Bladeren PJ Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469 [TBL] [Abstract][Full Text] [Related]
37. Cross-linking of DNA in L1210 cells and nuclei treated with cyclophosphamide and phosphoramide mustard. Surya YA; Rosenfeld JM; Hillcoat BL Cancer Treat Rep; 1978 Jan; 62(1):23-9. PubMed ID: 564237 [TBL] [Abstract][Full Text] [Related]
38. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Chan KK; Hong PS; Tutsch K; Trump DL Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837 [TBL] [Abstract][Full Text] [Related]
39. O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide. Zon G; Ludeman SM; Sweet EM; Egan W; Phillips LR J Pharm Sci; 1982 Apr; 71(4):443-6. PubMed ID: 7086655 [TBL] [Abstract][Full Text] [Related]
40. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Parekh HK; Sladek NE Biochem Pharmacol; 1993 Sep; 46(6):1043-52. PubMed ID: 8216347 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]